FAQs

Is the TMF Reference Model applicable to the investigator site file / regulatory binder?

The TMF Reference Model is intended to cover the full scope of the Trial Master File as described in ICH E6 Good Clinical Practice Guidelines. ICH E6 GCP Guidelines include all the content that the sponsor is required to maintain in the sponsor TMF and all the content that the investigator is required to maintain

Is the TMF Reference Model applicable to the investigator site file / regulatory binder? Read More »

v3 Query: IRB/IEC Artifacts

Question: It appears that “acknowledgement of receipt” is now specifically noted as a sub-artifact under IRB or IEC Submission, while “documentation received from the IRB/IEC in response to submission indicating acknowledgement” remains within the definition of IRB or IEC Approval. Can you confirm and clarify any intended distinction? Answer: An Acknowledgement of Receipt in 4.1.1 is

v3 Query: IRB/IEC Artifacts Read More »

I do not understand why artifact [xyz] is included in the TMF Reference Model

  Question: I do not understand why artifact [xyz] is included in the TMF Reference Model as there doesn’t seem to be a regulatory requirement for it to be included. Answer: If there is a specific regulatory requirement for an artifact or the general opinion of the TMF Reference Model Community based on past experience is

I do not understand why artifact [xyz] is included in the TMF Reference Model Read More »

Should draft documents be filed in the Trial Master File?

Unanimous opinion across the TMF Reference Model is that draft versions of documents should not be kept in the TMF, including versions with track changes. Key reasons include: Maintaining drafts and annotations can highlight issues that don’t exist such as comments not followed up or opinions not agreed with; There is no obligation to action

Should draft documents be filed in the Trial Master File? Read More »